Intensity Therapeutics (Intensity Therapeutics) Change In Inventory : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Intensity Therapeutics Change In Inventory?

Intensity Therapeutics's change in inventory for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Intensity Therapeutics's inventory stayed the same from Dec. 2023 to Mar. 2024 .

Intensity Therapeutics's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Intensity Therapeutics's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Intensity Therapeutics's Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Intensity Therapeutics Change In Inventory Historical Data

The historical data trend for Intensity Therapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intensity Therapeutics Change In Inventory Chart

Intensity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Intensity Therapeutics Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Inventory	Get a 7-Day Free Trial											-	-	-	-	-

Intensity Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Intensity Therapeutics (NAS:INTS) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Intensity Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Intensity Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Intensity Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Intensity Therapeutics Change In Inventory Related Terms

Thank you for viewing the detailed overview of Intensity Therapeutics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Intensity Therapeutics (Intensity Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intensity Therapeutics Inc (NAS:INTS) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

61 Wilton Road, 3rd Floor, Westport, CT, USA, 06880

Website

https://www.intensitytherapeutics.com

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors.

Executives

Emer Leahy	director	1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH FL 33139
Daniel Donovan	director	712 VISTA BLVD #305, WACONIA MN 55387
James M Ahlers	officer: Executive VP of CF	2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Lewis H Bender	director, 10 percent owner, officer: President and CEO	765 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Mark A Goldberg	director	PERCEPTIVE INFORMATICS INC, 200 WEST STREET, WALTHAM MA 02451
John M Wesolowski	officer: Interim CFO	61 WILTON ROAD, 3RD FLOOR, WESTPORT CT 06880